US Stock MarketDetailed Quotes
RLAY Relay Therapeutics
- 9.510
- +3.270+52.40%
Close Sep 9 16:00 ET
- 9.200
- -0.310-3.26%
Post 20:02 ET
1.27BMarket Cap-3773P/E (TTM)
10.720High7.810Low19.07MVolume8.050Open6.240Pre Close181.84MTurnover20.14%Turnover RatioLossP/E (Static)133.89MShares12.14052wk High1.87P/B900.28MFloat Cap5.70052wk Low--Dividend TTM94.67MShs Float64.370Historical High--Div YieldTTM46.64%Amplitude5.700Historical Low9.536Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Relay Therapeutics Stock Forum
3 MINUTES AGO, 6:55 AM EDT
VIA GLOBENEWSWIRE
9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D
33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D
Favorable overall tolerability profile; at RP2D, only 2 patients discontinued treatment due to adverse...
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
Relay Therapeutics announced positive interim data for RLY-2608, a pan-mutant and isoform-selective inhibitor of PI3Kα, in treating PI3Kα-mutated, HR+/HER2- metastatic breast cancer. Key findings include:
- 9.2-month median progression-free survival (PFS) in heavily pre-treated patients at the recommended Phase 2 dose (RP2D)
- 33% overal...
they just needed a catalyst from rate cuts and this expectation is enough to tr...
rate cut by fed is needed as a key catalyst
Relay Therapeutics Announces Clinical Trial Collaboration With Pfizer to Evaluate Atirmociclib in Combination With Rly-2608
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx (ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics (ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics (BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals (CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals (DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics (FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals (FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...
No comment yet